
Case report

A Case of Stevens-Johnson syndrome in recurrent late-stage ovarian cancer patient after management of chronic pain with elastomeric pump.

Andrej Cokan^{1,2,*}, Vida Gavrić Lovrec^{2,3}, Iztok Takac^{2,4}

¹ Department for gynaecological and breast oncology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; cokan.andrej@gmail.com (A.C.)

² Medical faculty, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia

³ Department for reproductive medicine and gynaecological endocrinology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; vida.gavric@ukc-mb.si (V.G.L.)

⁴ Clinic for gynaecology and perinatology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia; iztok.takac@ukc-mb.si (I.T.)

* Correspondence: cokan.andrej@gmail.com

Abstract: 1) Background. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, characterized by extensive necrosis and detachment of the epidermis. 2) Case presentation. We present a case of a 46-year-old patient with late-stage high-grade serous ovarian cancer who was primarily treated with neoadjuvant chemotherapy and interval debulking which was followed by adjuvant chemotherapy. At first recurrence, she was again treated with chemotherapy and due to severe abdominal pain, an elastomeric pump containing analgesics, anti-inflammatories and ondansetron was administered. In the same month, she was admitted to the hospital due to severe dysphagia and in the following days, she developed haemorrhagic vesiculobullous lesions on facial skin and trunk. Stevens-Johnson syndrome was confirmed and ondansetron as a leading cause was discontinued. Despite multimodal treatment, her condition deteriorated, and she died. 3) Discussion and conclusion. Although gynaecologists rarely encounter Stevens-Johnson syndrome, high mortality of the disease should ensure a low threshold for diagnosing and treating this disease.

Keywords: ondansetron; ovarian cancer; Stevens-Johnson syndrome.

1. Introduction

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions, which are considered a delayed-type hypersensitivity reaction to medication and are characterized by extensive necrosis and detachment of the epidermis [1]. Both are rare diseases, uncommon in the field of gynaecological oncology. They are associated with a wide array of medications, ondansetron being a possible, but quite rare cause of the disease [2]. Treatment of this condition requires a multidisciplinary approach and consists of supportive treatment, local skin and mucosal membranes care, ocular management and different adjunctive therapies. SCORTEN score (SCORE of Toxic Epidermal Necrosis) is used for predicting and assessing mortality rate for a certain patient based on independent risk factors. Mortality rate is high despite all treatment options and is higher in cancer patients.

2. Case presentation

We present a 46-year-old patient with late-stage high-grade serous ovarian cancer with SJS, presumably due to therapy with ondansetron.

She first came to our clinic in April 2018 with clinical and ultrasonographic signs of ovarian cancer. Diagnostic laparoscopy with biopsy confirmed high grade serous ovarian cancer (p53+, ER+ in 90%, PR -, WT-1+, CK7+, p53+). The disease was primarily inoperable, FIGO stage IVA, so neoadjuvant chemotherapy was suggested. After five cycles of paclitaxel with carboplatin, the extent of the disease was re-evaluated. Adequate regression of the disease on CT scans was observed, so we performed an interval cytoreduction (total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy, appendectomy, resection of parts of small bowel and sigma with the formation of the stoma). Surgery was not radical, with remaining lesions on the right and left diaphragm. After surgery patient received two more cycles of paclitaxel with carboplatin. Treatment was completed in January 2019 when the patient was offered to continue treatment with bevacizumab which she refused. The first recurrence was diagnosed in July 2019 with elevated Ca125 and with CT scans showing enlarged retroperitoneal lymph nodes, a lesion in the right pulmonary lobe and enlarged pericardial lymph nodes. She became symptomatic in September 2019 when she presented with ascites. We offered her chemotherapy round 2 with carboplatin and liposomal doxorubicin. During this treatment, she experienced severe abdominal pain which was treated predominantly with morphine. Left side hydronephrosis also developed and was treated with percutaneous nephrostomy. After receiving 7 cycles of adjuvant chemotherapy, due to BRCA positive result, olaparib was offered but she again refused the proposed treatment. To relieve severe abdominal pain, elastomeric pump was implanted at the beginning of August 2020, containing morphine, esketamine, dexamethasone, xylocaine and ondansetron. At the end of August 2020, the patient was admitted to the hospital because of elevated body temperature, dysphagia and difficulties breathing. Acute pharyngitis was suspected and Co-amoxiclav (1,2 g IV tid) was introduced. After two days, round red lesions, macules and plaques, which were present periocularly and on the trunk started emerging, so she was examined by an infectologist and dermatologist. Laboratory findings included elevated CRP, PCT, bicytopenia with monocytic predominance, electrolyte disbalance and hypoalbuminemia. Atypical pneumonia and SJS were suspected, so antibiotic treatment was changed to moxifloxacin (400 mg IV qd) and flucloxacillin (2g IV qid) and we also introduced methylprednisolone (40 mg IV qd) with pantoprazole (40 mg IV qd) and local therapy for severely affected skin on the trunk (betamethasone lotion), vulva (betamethasone/gentamicin lotion), around lips (triamcinolone), and eyes (chloramphenicol lotion in the left eye and dexamethasone/neomycin/polymyxin B lotion in the right eye). Ondansetron as a most likely cause of the syndrome was discontinued, but despite that, skin lesions deteriorated with the additional appearance of haemorrhagic vesiculobullous lesions especially on the facial skin which we treated with silicone and polyurethane patches and sodium fusidate (Figure 1). SCORTEN score 3 was calculated. Analgesic therapy (PCA pump with 80 mg of morphine, 50 mg of cetanest, 10% lidocaine with up to 1000 ml of saline solution), electrolytes, fluids and total parenteral nutrition were administered. On the fifth day of treatment, approximately 8-10% of skin was affected. CRP was still elevated, and elevated body temperature rose to 39°C. The antibiotic regimen was changed to piperacillin/tazobactam (4,5 g IV tid) which resulted in the drop of inflammatory markers, although the general condition of the patient did not improve. In the following days, we observed deterioration of liver function and thrombocytopenia. Also, due to less controllable pain because of severe skin lesions with exposure of deeper skin layers, we had to modify analgesic therapy with the addition of midazolam and higher doses of morphine. Despite all efforts of a multidisciplinary team (infectologists, dermatologists, ophthalmologists, gynaecologists and plastic surgeons) the patient's general condition further deteriorated and on the 12th day after being admitted to the hospital, she died.

Beforehand, written consent was obtained from the patient, allowing publication of the case report and all accompanying graphic material.



Figure 1. Haemorrhagic vesiculobullous lesions on facial skin and trunk.

3. Discussion

SJS/TEN is a very serious drug-adverse mucocutaneous reaction with a high mortality rate despite all available treatment options. Both diseases are rare, SJS being three times more common than TEN and the joint incidence is about 1-7/1000000 per year [3]. The incidence is higher in immunodeficient and cancer patients and women [3]. Medications, such as allopurinol, lamotrigine, sulfasalazine, nevirapine, nonsteroidal anti-inflammatory drugs, phenobarbital, carbamazepine, paracetamol, penicillin such as amoxicillin or ampicillin and various anticancer drugs are thought to be the leading trigger for developing the disease [4–5]. Treatment is multidisciplinary and consists of supportive care (wound care, fluids and nutrition [6], pain control, prevention and treatment of infections and prevention of vulvovaginal sequelae), ocular management and different adjunctive therapies (systemic corticosteroids, intravenous immune globulin, cyclosporine, thalidomide, tumour necrosis factor inhibitors and plasmapheresis) [7–10]. Despite multiple treatment options, mortality is still high and can range from 10% for SJS to up to 30% or more for TEN [11]. Acute respiratory distress syndrome, sepsis and multiple organ failure are the most common causes of in-hospital death. Patients above 70 years of age with comorbidities, such as metastatic cancer or liver diseases, are also associated with an increased risk of death [12].

As a prediction score, SCORTEN scale or score is used widely by clinicians to determine which clinical setting is appropriate for the management of the individual patient and for discussing a patient's prognosis [13].

Although ovarian neoplasm or more specific a treatment for ovarian neoplasm and ondansetron, on the other hand, have been mentioned separately as a possible cause for the development of the disease, both causes are very rare [14]. As gynaecologists, we are rarely subjected to recognizing and treating these diseases, which are also more fatal in our cancer patients, probably due to their immunocompromised state [15].

In our case, the patient already completed cancer-specific treatment and at the time she presented with the first symptoms which then progressed into the SJS, did not receive any cancer-specific therapy. Also, different antibiotic regimens were applied later, so ondansetron, which was prescribed in an elastomeric pump to alleviate sickness due to opioid therapy, was suspected to be the cause for the onset of the disease. Despite identifying

the most probable cause for the disease development and applying multimodality treatment, she deteriorated rapidly, with the development of sepsis and liver failure and finally died only 12 days after being admitted to the hospital.

Although SJS/TEN is quite rare in gynaecological cancer patients, we should be aware, that especially in ovarian cancer patients, who are exposed to prolonged multimodality treatment with surgery, chemotherapy and biological agents, treatment can be accompanied by various signs and symptoms, such as infections, chronic pain, malaise, vomiting and obstipation, which are treated with multiple medications, the occurrence of this disease is possible and is associated with very high morbidity and mortality.

Author Contributions: All authors have read and agreed to the published version of the manuscript. All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Funding: This study has not benefited from any fund.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors have no conflict of interest to declare.

References

1. Stern, R. S.; Divito, S. J., Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and Pathobiology – Thirty years of progress but still much to be done. *Journal of Investigative Dermatology* 2017, 137 (5), 1004-1008.
2. Saraogi, P. P.; Nayak, C. S.; Pereira, R. R.; Dhurat, R. S., Inadvertent provocative oral ondansetron use leading to toxic epidermal necrolysis in an HIV-infected patient. *Indian Journal of Dermatology* 2012, 57 (6), 503.
3. Sekula, P.; Dunant, A.; Mockenhaupt, M.; Naldi, L.; Bavinck, J. N. B.; Halevy, S.; Kardaun, S.; Sidoroff, A.; Liss, Y.; Schumacher, M., Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. *Journal of Investigative Dermatology* 2013, 133 (5), 1197-1204.
4. Collins, L. K.; Chapman, M. S.; Carter, J. B.; Samie, F. H., Cutaneous adverse effects of the immune checkpoint inhibitors. *Current problems in cancer* 2017, 41 (2), 125-128.
5. Paulmann, M.; Mockenhaupt, M., Fever in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases: Laboratory Work-up and Antibiotic Therapy. *The Pediatric infectious disease journal* 2017, 36 (5), 513-515.
6. Creamer, D.; Walsh, S. A.; Dziejwulski, P.; Exton, L. S.; Lee, H. Y.; Dart, J. K.; Setterfield, J.; Bunker, C. B.; Ardern-Jones, M. R.; Watson, K. M.; Wong, G. A.; Philippidou, M.; Vercueil, A.; Martin, R. V.; Williams, G.; Shah, M.; Brown, D.; Williams, P.; Mohd Mustapa, M. F.; Smith, C. H., U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *The British journal of dermatology* 2016, 174 (6), 1194-227.
7. Chang, Y.-S.; Huang, F.-C.; Tseng, S.-H.; Hsu, C.-K.; Ho, C.-L.; Sheu, H.-M., Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. *Cornea* 2007, 26 (2), 123-129.
8. Huang, Y.-C.; Chien, Y. N.; Chen, Y. T.; Li, Y. C.; Chen, T. J., Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. 2016.
9. Ng, Q. X.; De Deyn, M. L. Z. Q.; Venkatanarayanan, N.; Ho, C. Y. X.; Yeo, W.-S., A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis. *Journal of inflammation research* 2018, 11, 135.
10. Wang, C.-W.; Yang, L.-Y.; Chen, C.-B.; Ho, H.-C.; Hung, S.-I.; Yang, C.-H.; Chang, C.-J.; Su, S.-C.; Hui, R. C.-Y.; Chin, S.-W., Randomized, controlled trial of TNF- α antagonist in CTL-mediated severe cutaneous adverse reactions. *The Journal of clinical investigation* 2018, 128 (3), 985-996.
11. Mockenhaupt, M.; Bastuji-Garin; Salopek; Auquier-Dunant; Rzany; Ziemer; Liss; Mockenhaupt; Mockenhaupt; Sidoroff, The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. *Expert review of clinical immunology* 2011, 7 (6), 803-815.
12. Ezaldein, H.; Totonchy, M.; Chow, C.; Samuel, A.; Ventura, A., The effect of comorbidities on overall mortality in Stevens-Johnson Syndrome: an analysis of the Nationwide Inpatient Sample. *Dermatology Online Journal* 2017, 23 (4).
13. Torres-Navarro, I.; Briz-Redón, Á.; Botella-Estrada, R., Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. *Journal of the European Academy of Dermatology and Venereology* 2020, 34 (9), 2066-2077.

-
14. 14. Giaccone, G.; Risio, M.; Bonardi, G.; Calciati, A., Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report. *Tumori Journal* 1986, 72 (3), 331-333.
 15. 15. Gillis, N. K.; Hicks, J. K.; Bell, G. C.; Daly, A. J.; Kanetsky, P. A.; McLeod, H. L., Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. *The Journal of investigative dermatology* 2017, 137 (9), 2021.